Los Angeles Capital Management
AVBP icon

Los Angeles Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Los Angeles Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,308
Closed -$399K – 2523
2026
Q1 		$399K Sell
17,308
-22,992
-57% -$519K ﹤0.01% 943
2025
Q4 		$744K Buy
+40,300
New +$839K ﹤0.01% 751

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Los Angeles Capital Management's AVBP Position: Q2 2026 in Review

Los Angeles Capital Management sold out of ArriVent BioPharma (AVBP) in Q2 2026, closing a stake of 17,308 shares — an estimated $399K sold.

Los Angeles Capital Management first reported a position in AVBP in Q4 2025 and held it in 2 quarters. The position peaked at $744K in Q4 2025. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Los Angeles Capital Management reported no remaining ArriVent BioPharma position as of Q2 2026 after selling out during the quarter.
  • Los Angeles Capital Management sold 17,308 ArriVent BioPharma shares in Q2 2026, an estimated $399K.
  • Los Angeles Capital Management first reported a position in ArriVent BioPharma in Q4 2025 and held it in 2 quarters.
  • Los Angeles Capital Management's ArriVent BioPharma position peaked at $744K in Q4 2025.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.